2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2440

First Results from the Prospective German Pregnancy Register
Abstract Number: 1594

First-in-Human Pharmacokinetics and Safety of Escalating Single- and Multiple-Doses of GS-9876, a Novel, Oral SYK Inhibitor, in Healthy Subjects
Abstract Number: 950

Flares after Withdrawal of Biotherapies in JIA: Clinical and Laboratory Correlates of Remission Duration
Abstract Number: 2072

Fli1-Haploinsufficient Dermal Fibroblasts Promote Skin-Localized Transdifferentiation of Th2- and Th17-like Regulatory T Cells
Abstract Number: 163

Fluorescence Optical Imaging Reveals Distinct Patterns of Hand Joint Inflammation in Seropositive and Seronegative Early Rheumatoid Arthritis
Abstract Number: 1504

Fluoroquinolone Resistance in Escherichia coli Urinary Tract Infections Among Patients with Rheumatoid Arthritis: Does Use of Hydroxichloroquine Matter?
Abstract Number: 2309

Focal Myositis: New Insights on Diagnosis and Pathology
Abstract Number: 883

Folate Receptor Beta and Endothelin Receptor Beta Macrophage Subtypes Are Differentially Expressed in the Vascular Compartments of the Intima and Media/Adventitia in Giant Cell Arteritis: A Pilot Study
Abstract Number: 2123

Follistatin-like Protein 1 Is a Potent Regulator of Articular Chondrocytes in Osteoarthritis
Abstract Number: 400

Foot Involvement in Enthesitis-Related Arthritis Subtype of Juvenile Idiopathic Arthritis: Clinical, Radiological and Functional Assessment
Abstract Number: 847

Forced Vital Capacity Predicts Lung Fibrosis Progression and Mortality in Systemic Sclerosis
Abstract Number: 843

Forced Vital Capacity Predicts Outcome in Scleroderma Associated Interstitial Lung Disease with Concomitant Pulmonary Hypertension: Data from the Pharos Registry
Abstract Number: 2913

Four Year Effects of Combined Bosentan and Iloprost Treatment on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion and Clinical Status, in Systemic Sclerosis Patients
Abstract Number: 1042

Four Year Imaging Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol, Including Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Abstract Number: 1795

Four Years Follow-up of Subclinical Atherosclerosis in Systemic Lupus Erythematosus Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].